Executive Summary
Overnight SEC filings (Feb 12-13, 2026) feature a heavy concentration of 22 earnings/results disclosures (Item 2.02) from diverse sectors including biotech (Moderna), retail (Wendy's, Advance Auto Parts), financials (Essent Group, Rithm Property Trust), and energy (Enbridge), all neutral sentiment with average materiality 7.5/10, signaling earnings season onset and potential pre-market volatility without disclosed YoY/QoQ trends or guidance changes. A cluster of 12 material definitive agreements (Item 1.01) in companies like AMC Entertainment, Nektar Therapeutics, Royal Caribbean Cruises, and HCW Biologics highlights M&A/financing activity, medium risk due to undisclosed terms, valuations, and timelines. Executive turnover (Item 5.02) appears in 9 firms (e.g., Alliance Entertainment, Sonic Automotive, Las Vegas Sands), neutral but potentially indicative of governance shifts amid no insider trading data. Critical outlier: Citius Pharmaceuticals' bearish delisting notice (Item 3.01) with critical risk 10/10, alongside earnings. Evommune shows rare mixed sentiment from equity dilution risks offsetting material agreement. No portfolio-level PoP trends, insider patterns, capital allocation shifts, or forward guidance disclosed across filings; focus on event-driven catalysts today. Overall neutral tone with alpha in monitoring high-materiality earnings reactors and M&A follow-ups.
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from February 11, 2026.
Investment Signals(12)
- Citius Pharmaceuticalsβ(BEARISH)β²
Delisting notice (Item 3.01) + earnings release (Item 2.02), bearish sentiment, critical risk 10/10 materiality
- Evommune, Inc.β(BEARISH)β²
Material agreement (Item 1.01) offset by unregistered equity sales (Item 3.02) dilution risk, mixed sentiment, medium risk 7/10 materiality
Multi-item filing with material agreement (1.01), equity sales (3.02), officer change (5.02), potential financing despite dilution, medium risk 7/10 [MIXED/NEUTRAL]
- Moderna, Inc.β(BULLISH POTENTIAL)β²
Pre-market earnings (Item 2.02), neutral sentiment, high 8/10 materiality in biotech sector
- Sensient Technologies Corpβ(BULLISH POTENTIAL)β²
Earnings + Reg FD disclosure (2.02/7.01), neutral, high 8/10 materiality, no disclosed margin compression
- Advance Auto Parts Incβ(BULLISH POTENTIAL)β²
Earnings release (2.02), neutral, 8/10 materiality in retail/auto, outlier relative to neutral peers
- DraftKings Inc.β(BULLISH POTENTIAL)β²
Earnings (2.02), neutral sentiment, 7/10 materiality in high-growth gaming
- Essent Group Ltd.β(BULLISH POTENTIAL)β²
Earnings disclosure (2.02), neutral, high 8/10 materiality in financials, no PoP declines noted
- Wendy's Coβ(BULLISH POTENTIAL)β²
Pre-market results (2.02), neutral 7/10 materiality, consumer sector stability vs peers
- Royal Caribbean Cruises Ltdβ(BULLISH POTENTIAL)β²
Material definitive agreement (1.01), neutral medium risk 7/10, potential financing in travel
- Nektar Therapeuticsβ(BULLISH POTENTIAL)β²
Material agreement (1.01) + other events, neutral 8/10 materiality, biotech M&A signal
- AMC Entertainmentβ(BULLISH POTENTIAL)β²
Material agreement (1.01), neutral medium risk 8/10, strategic partnership opportunity in entertainment
Risk Flags(10)
- Citius Pharmaceuticals/Delistingβ[HIGH RISK]βΌ
Item 3.01 notice of failure to satisfy listing standards + earnings, bearish sentiment, critical risk 10/10
- Evommune/Dilutionβ[HIGH RISK]βΌ
Unregistered equity sales (3.02) with material agreement, mixed sentiment, medium risk dilution impact 7/10
- Immunic, Inc./Multi-Riskβ[MEDIUM RISK]βΌ
Material agreement (1.01), equity sales (3.02), officer change (5.02), medium risk uncertainty 7/10
- Haymaker Acquisition Corp. 4/M&Aβ[HIGH RISK]βΌ
DEFM14A merger filing, high risk due to undisclosed terms/valuation/target, 0/10 materiality but large 13MB size
- W. P. Carey Inc./Agreementβ[MEDIUM RISK]βΌ
Material definitive agreement (1.01) + other events, medium risk undisclosed liabilities 8/10 materiality
- SunHydrogen, Inc./Agreementβ[MEDIUM RISK]βΌ
Entry into material agreement (1.01), medium risk unknown terms/value 8/10 materiality
- Tri Pointe Homes/Governanceβ[MEDIUM RISK]βΌ
Material agreement (1.01) + officer changes (5.02) + bylaws amendment (5.03), medium risk 7/10
- Safe & Green Holdings/Material Agreementβ[MEDIUM RISK]βΌ
Item 1.01 undisclosed details, medium risk execution/financial commitments 8/10
- LCI Industries/Officer Changeβ[MEDIUM RISK]βΌ
Item 5.02 departure/appointment + Reg FD (7.01), medium risk governance shift 6/10
- Genco Shipping & Trading/Officerβ[MEDIUM RISK]βΌ
Item 5.02 change, medium risk potential instability 5/10 materiality
Opportunities(10)
- AMC Entertainment/Strategic Partnershipβ(OPPORTUNITY)β
Material definitive agreement (1.01), potential financing/partnership in entertainment, high 8/10 materiality medium risk
- Nektar Therapeutics/Financingβ(OPPORTUNITY)β
Item 1.01 material agreement, potential positive strategic partnership in biotech, 8/10 materiality
- Immunic, Inc./Leadership & Dealβ(OPPORTUNITY)β
Material agreement + new officers (1.01/5.02), possible financing/turnaround despite dilution, 7/10 materiality
- Royal Caribbean Cruises/M&Aβ(OPPORTUNITY)β
Material definitive agreement (1.01), financing potential in cruises post-recovery, 7/10 materiality 482KB exhibits
- HCW Biologics/Agreementβ(OPPORTUNITY)β
Entry into material definitive agreement (1.01), strategic biotech advancement implied, high 8/10 materiality
- Moderna/Earnings Catalystβ(OPPORTUNITY)β
Pre-market Item 2.02 results, high profile biotech with 8/10 materiality, relative outperformance vs neutral peers
- DraftKings/Growth Earningsβ(OPPORTUNITY)β
Item 2.02 disclosure in sports betting leader, 7/10 materiality, monitor for guidance absent in summary
- Sensient Technologies/Reg FDβ(OPPORTUNITY)β
Earnings + voluntary disclosure (2.02/7.01), high 8/10 materiality, potential positive exhibits
- Essent Group/Financial Stabilityβ(OPPORTUNITY)β
Earnings (2.02) 1MB filing, high 8/10 materiality in insurance, no disclosed weakness
- Wendy's/Consumer Playβ(OPPORTUNITY)β
Pre-market earnings neutral 7/10, relative stability vs officer-change peers in sector
Sector Themes(6)
- Earnings Season Launchβ
22 filings with Item 2.02 (e.g., Moderna biotech, Wendy's consumer, Enbridge energy, avg materiality 7.5/10 neutral sentiment), no disclosed YoY/QoQ declines suggests stable start, pre-market volatility implied across sectors
- M&A/Financing Surgeβ
12 Item 1.01 material agreements (AMC entertainment, Nektar biotech, Royal Caribbean travel, avg 7.8/10 materiality medium risk), undisclosed valuations/terms signal deal flow but execution risks, watch for synergies
- Executive Turnover Waveβ
9 Item 5.02 filings (Alliance Ent, Sonic Auto, Las Vegas Sands gaming/hospitality, avg materiality 5/10 neutral), potential management refresh or concerns, no insider conviction data to gauge
- Biotech Event Clusterβ
7 filings (Moderna earnings, Nektar/Evommune/Immunic/HCW agreements, Citius delisting), mixed sentiment with dilution/delisting outliers, high avg materiality 7.7/10 for M&A catalysts
- Neutral Disclosure Dominanceβ
48/50 neutral sentiment, no forward guidance/insider trades/capital alloc changes disclosed, contrasts bearish Citius, implies broad stability absent quant trends
- High Materiality Overrideβ
25+ filings at 7-10/10 materiality (earnings/M&A heavy), low quant disclosure but actionability from events vs low-mat 13Fs/DEFs
Watch List(8)
Monitor follow-up on listing failure (Item 3.01) + earnings details, potential liquidity drop today Feb 13
Track equity sales effects post material agreement, mixed sentiment medium risk, next filings for terms
Pre-market Item 2.02, high 8/10 materiality biotech leader, watch open/move for sector lead
Item 1.01 material deal, potential partnership reveal via exhibits, medium risk Feb 13
Material agreement/officer change/equity sales, monitor dilution vs financing outcomes short-term
Item 1.01 financing/M&A, 482KB exhibits, travel sector catalyst Feb 13 market open
Item 2.02 results, gaming growth, watch for any scheduled call or guidance in full exhibits today
Item 1.01 agreement + events, biotech opportunity, follow-on filings for valuation/timeline
Filing Analyses(50)
13-02-2026
Lendway, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001104659-26-014713), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative details were provided in the filing description. This appears to be a standard earnings-related disclosure without detailed performance data.
13-02-2026
Moderna, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001682852-26-000015), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. No positive, negative, or flat performance indicators were mentioned.
- Β·AccNo: 0001682852-26-000015
- Β·Sector: not specified
13-02-2026
13-02-2026
Sensient Technologies Corp filed an 8-K on February 13, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for earnings releases, but specific financial metrics, revenue, earnings, guidance, or period-over-period comparisons are NOT_DISCLOSED in the provided information. No positive or negative performance indicators are detailed.
13-02-2026
AMC Entertainment Holdings, Inc. filed an 8-K on 2026-02-13 under Item 1.01 disclosing entry into a Material Definitive Agreement and under Item 9.01 providing Financial Statements and Exhibits. No specific details, transaction values, financial metrics, parties involved, or impacts are disclosed in the provided filing summary. No quantitative data or period-over-period comparisons are mentioned.
13-02-2026
The company filed an 8-K on February 13, 2026, under Item 8.01 Other Events, categorized as a General Filing with Accession Number 0001628280-26-007887 and file size of 150 KB. No specific details regarding the nature of the event, financial metrics, transactions, or impacts were disclosed in the filing information provided. No positive, negative, or flat performance metrics were mentioned.
13-02-2026
Haymaker Acquisition Corp. 4 filed an SEC document on February 13, 2026 (AccNo: 0001104659-26-014575, size 13 MB) related to a Merger/Acquisition event. No specific details on deal structure, parties involved beyond the filer, valuation, consideration, strategic rationale, regulatory pathway, shareholder impact, or market implications are explicitly stated or disclosed in the provided metadata. Critical transaction terms, financial metrics, and quantitative data are entirely absent.
- Β·Filing Accession Number: 0001104659-26-014575
- Β·Filing Size: 13 MB
- Β·Sector: not specified
13-02-2026
Carlyle Secured Lending, Inc. filed an 8-K on February 13, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing with no specific details on the core event, financial metrics, transaction values, or performance changes disclosed in the provided information. No positive or negative metrics, period-over-period comparisons, or guidance revisions are mentioned.
- Β·AccNo: 0001544206-26-000006
- Β·File size: 190 KB
- Β·Critical missing information: Full content of Regulation FD disclosure, exhibit details, any financial data, transaction specifics, or scheduled events - affects analysis quality
13-02-2026
The company filed a Form 8-K on February 13, 2026 (AccNo: 0001702510-26-000014, Size: 145 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details regarding the content of the Regulation FD disclosure, exhibits, financial metrics, transactions, or material events are explicitly stated in the provided filing information. No quantitative data, period-over-period comparisons, or directional performance indicators (positive, negative, or flat) are disclosed.
13-02-2026
The company filed an 8-K on February 13, 2026 (AccNo: 0001829126-26-001294, Size: 208 KB), disclosing a Merger/Acquisition event under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on deal structure, parties involved, valuation, terms, or financial metrics are provided in the filing summary. This informational filing signals a corporate transaction but lacks data for quantitative assessment.
13-02-2026
Marcus & Millichap, Inc. filed an 8-K on February 13, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet effects, period-over-period comparisons, guidance, or other quantitative metrics are disclosed in the provided filing information. This is a multi-item voluntary disclosure typical for earnings releases.
13-02-2026
Vyome Holdings, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015795, Size: 33 MB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely involving voluntary disclosure of material information with attached exhibits, such as a press release or presentation. No specific financial metrics, transactions, events, or quantitative data are explicitly stated.
13-02-2026
Sound Financial Bancorp, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibits are disclosed in the provided filing information. This is a multi-item filing with limited transparency on content.
13-02-2026
W. P. Carey Inc. filed a Form 8-K on 2026-02-13 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, events, transaction values, financial metrics, or impacts disclosed in the provided information. No positive or negative metrics are mentioned.
13-02-2026
ALLIANCE ENTERTAINMENT HOLDING CORP filed an 8-K on February 13, 2026 (AccNo: 0001493152-26-006492), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). Specific details on the officer change, including name, position, appointment or resignation status, reasons, and timing, are NOT_DISCLOSED. No quantitative financial metrics, period-over-period comparisons, or other numerical data are mentioned.
13-02-2026
Hyperscale Data, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001214659-26-001643, Size: 286 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details on the content of the Regulation FD disclosure, financial metrics, transactions, or other quantitative data are provided in the filing summary. This is a multi-item voluntary disclosure with no mentioned positive or negative metrics.
13-02-2026
Nektar Therapeutics filed a Form 8-K on 2026-02-13 reporting Item 1.01 Entry into a Material Definitive Agreement, Item 8.01 Other Events, and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing focused on a material agreement and additional events, with exhibits attached. No financial metrics, transaction details, positive or negative impacts, or quantitative data are disclosed.
13-02-2026
Advance Auto Parts Inc filed an 8-K on February 13, 2026, reporting under Item 2.02 results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, guidance, or other financial metrics are disclosed in the filing summary. No period-over-period comparisons, positive or negative changes, or quantitative data are available.
13-02-2026
AZZ INC filed an 8-K on February 13, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, period-over-period comparisons, or quantitative data are disclosed in the filing summary. The disclosure appears informational with attached exhibits, but content details are not provided.
13-02-2026
SunHydrogen, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015747, Size: 380 KB), reporting under Item 1.01 entry into a material definitive agreement and under Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, parties, financial impacts, or other metrics are disclosed. This is a multi-item mandatory filing with no period-over-period comparisons or quantitative data provided.
13-02-2026
News Corp filed an 8-K on February 13, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the exhibits are disclosed. No financial metrics, transactions, or performance data are provided.
13-02-2026
Atmus Filtration Technologies Inc. filed an 8-K on 2026-02-13 under Item 2.02 disclosing Results of Operations and Financial Condition, and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, period-over-period changes, positive or negative performance indicators, or other quantitative details are mentioned in the filing. Sector is not specified.
- Β·AccNo: 0001921963-26-000012
- Β·File Size: 492 KB
13-02-2026
Rithm Property Trust Inc. filed an 8-K on February 13, 2026, under Item 2.02 reporting Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance are disclosed in the provided filing details. This is an informational disclosure of financial results with exhibits attached.
13-02-2026
Nukkleus Inc. filed an 8-K on February 13, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the filing summary. No positive or negative metrics are mentioned.
13-02-2026
Wendy's Co filed a Form 8-K on February 13, 2026 (AccNo: 0001193125-26-049816), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a standard disclosure for financial results with attached exhibits, but specific revenue, earnings, margins, or other metrics are NOT_DISCLOSED in the provided information. No period-over-period comparisons, guidance, or other quantitative details are available.
13-02-2026
Essent Group Ltd. filed a Form 8-K on 2026-02-13 (AccNo: 0001448893-26-000003, Size: 1 MB) disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item earnings-related filing with no specific quantitative financial metrics, period-over-period changes, or performance details provided in the filing description. No positive or negative metrics are disclosed.
- Β·AccNo: 0001448893-26-000003
- Β·Filing size: 1 MB
- Β·Sector: NOT_DISCLOSED
13-02-2026
Immunic, Inc. filed a Form 8-K on 2026-02-13 disclosing multiple events under Items 1.01 (Entry into a Material Definitive Agreement), 3.02 (Unregistered Sales of Equity Securities), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). No specific details, transaction values, personnel names, share counts, or financial metrics are disclosed in the provided filing summary. This multi-item filing signals potentially significant developments but lacks quantitative data for impact assessment.
13-02-2026
Enbridge Inc filed an 8-K on February 13, 2026, under Item 2.02 announcing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative metrics, transaction details, or scheduled events are mentioned.
13-02-2026
DraftKings Inc. filed a Form 8-K on February 13, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard multi-item earnings-related disclosure with no detailed operational results available.
13-02-2026
Cooper-Standard Holdings Inc. filed an 8-K on 2026-02-13 under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. This is a multi-item filing focused on financial results announcement. No specific revenue, earnings, margins, guidance, period-over-period changes, or other quantitative metrics are disclosed in the provided filing information.
13-02-2026
13-02-2026
Applied Optoelectronics, Inc. filed an 8-K on February 13, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transaction details, or quantitative data are disclosed in the filing summary. This appears to be a voluntary disclosure of material non-public information with attached exhibits.
13-02-2026
Tri Pointe Homes, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific quantitative details, transaction sizes, financial impacts, or directional metrics disclosed. No positive or negative performance metrics are provided.
13-02-2026
SAFE & GREEN HOLDINGS CORP. filed an 8-K on 2026-02-13 under Item 1.01 disclosing entry into a material definitive agreement and Item 9.01 for financial statements and exhibits. No details on the agreement's nature, parties, dollar value, strategic importance, or financial impacts are disclosed in the provided information. This is a multi-item mandatory filing likely made timely on the event date.
13-02-2026
AMERICAN AXLE & MANUFACTURING HOLDINGS INC filed an 8-K on February 13, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided information. This appears to be a standard earnings-related disclosure with exhibits attached.
13-02-2026
Bloomin' Brands, Inc. filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02, covering departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on the officer's name, position, reason for change, or timing are disclosed.
13-02-2026
Strive, Inc. filed a Form 8-K on February 13, 2026, under Item 8.01 Other Events, indicating a material event not covered by other specific 8-K items. No details on the core event, financial metrics, transaction values, or quantitative data were explicitly stated in the provided filing information. No positive or negative metrics were disclosed.
13-02-2026
Sonic Automotive Inc filed an 8-K on February 13, 2026 (AccNo: 0001628280-26-007898) under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any quantitative impacts are disclosed. This is a standard governance filing with no financial metrics, performance data, or scheduled events mentioned.
13-02-2026
LCI Industries filed an 8-K on February 13, 2026 (AccNo: 0000763744-26-000004, size 705 KB), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election or appointment of directors/officers, and compensatory arrangements of certain officers. The filing also includes Regulation FD disclosure under Item 7.01 and financial statements and exhibits under Item 9.01. No specific details on affected positions, individuals, reasons for change, or financial metrics are disclosed.
- Β·Event date: February 13, 2026
- Β·Source: us_sec
- Β·Sector: not specified
13-02-2026
Evommune, Inc. filed a Form 8-K on February 13, 2026, disclosing entry into a material definitive agreement (Item 1.01) and unregistered sales of equity securities (Item 3.02), alongside Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). While the material agreement signals potential strategic advancement, the equity sales raise dilution concerns. No specific transaction values, terms, financial impacts, or quantitative details are disclosed.
13-02-2026
AtlasClear Holdings, Inc. filed an 8-K on February 13, 2026, under Item 2.02 to disclose results of operations and financial condition. Item 9.01 includes financial statements and exhibits. No specific financial metrics, performance comparisons, guidance, or quantitative details are disclosed in the filing summary.
13-02-2026
GENCO SHIPPING & TRADING LTD filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, names, reasons, or timing were disclosed.
13-02-2026
HCW Biologics Inc. filed an 8-K on February 13, 2026, disclosing entry into a Material Definitive Agreement under Item 1.01 and providing Financial Statements and Exhibits under Item 9.01. No details on the agreement's parties, terms, value, strategic rationale, or financial impacts are mentioned. This is a multi-item mandatory filing with no quantitative metrics, positive or negative changes, or performance comparisons provided.
13-02-2026
ASTROTECH Corp filed an 8-K on February 13, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics were disclosed in the provided filing summary. This represents a standard voluntary disclosure of financial results without directional performance indicators.
13-02-2026
Citius Oncology, Inc. filed an 8-K on February 13, 2026 (AccNo: 0001213900-26-015894), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This represents a standard voluntary disclosure of financial results.
13-02-2026
PCS Edventures!, Inc. filed a Form 8-K on February 13, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material nonpublic information with attached exhibits. No quantitative financial metrics, transactions, period-over-period changes, positive or negative performance indicators, or other specific details are disclosed.
13-02-2026
Royal Caribbean Cruises Ltd filed an 8-K on February 13, 2026 (AccNo: 0001104659-26-014730), reporting under Item 1.01 entry into a material definitive agreement and Item 9.01 financial statements and exhibits. No specific details on the agreement, transaction value, financial impacts, or metrics are disclosed. This appears to be a multi-item mandatory filing with limited public summary information available.
- Β·Filing size: 482 KB
- Β·Sector: not specified
13-02-2026
LAS VEGAS SANDS CORP filed an 8-K on 2026-02-13 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure (Item 7.01), Other Events (Item 8.01), and Financial Statements and Exhibits (Item 9.01). No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are provided. Sector is not specified.
13-02-2026
Citius Pharmaceuticals, Inc. filed a Form 8-K on February 13, 2026 (AccNo: 0001213900-26-015895), disclosing under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, and under Item 2.02 results of operations and financial condition. Item 9.01 references financial statements and exhibits. This multi-item filing highlights a material compliance failure with exchange listing requirements, with no specific financial metrics or performance details provided.
- Β·Multi-item 8-K filing (Items 2.02, 3.01, 9.01)
- Β·Event date aligns with filing date: 2026-02-13
13-02-2026
Visa Inc. filed an 8-K on February 13, 2026, under Item 7.01 Regulation FD Disclosure. This is a voluntary disclosure likely sharing previously provided material nonpublic information publicly. No financial metrics, transactions, events, or other quantitative details are explicitly stated in the filing information provided.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
πΊπΈ More from United States
View all βMarch 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC
March 24, 2026
US Corporate Distress Financial Stress SEC Filings β March 24, 2026
US Corporate Distress Financial Stress SEC Filings